Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 12/20 | 0.65 |
| ▸ | CTSK | P43235 | 10/20 | 0.65 |
| ▸ | CTSB | P07858 | 4/20 | 0.65 |
| ▸ | CTSL | P07711 | 2/20 | 0.65 |
| ▸ | CTSC | P53634 | 4/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | ACE | P12821 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2329798 | 1.00 | CTSS (0.65) | CTSSCTSKCTSBCTSLCTSC | |
| SCHEMBL18262403 | 0.88 | CTSS (0.53) | CTSSCTSKCTSBCTSLCTSC | |
| SCHEMBL18262402 | 0.88 | CTSS (0.53) | CTSSCTSKCTSBCTSLCTSC | |
| SCHEMBL21013700 | 0.88 | CTSK (0.52) | CTSSCTSKCTSBCTSLCTSC | |
| SCHEMBL2402235 | 0.87 | CTSS (0.60) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL6292769 | 0.87 | CTSS (0.60) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL3922795 | 0.87 | CTSS (0.60) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL2074401 | 0.86 | CTSS (0.51) | CTSSCTSKCTSBCTSLCTSC | |
| SCHEMBL19969082 | 0.86 | CTSS (0.51) | CTSSCTSKCTSBCTSLCTSC | |
| SCHEMBL2074403 | 0.86 | CTSS (0.51) | CTSSCTSKCTSBCTSLCTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773775-B1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-08-17 | — | — | EP | disclosed |
| US-7429604-B2 | Six-membered heterocycles useful as serine protease inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-09-30 | — | — | US | disclosed |
| US-20060009455-A1 | especially blood coagulation factor XIa and plasma kallikrein; e.g. 4-aminomethyl-[2-phenyl-1-(4-phenyl-pyridin-2-yl)-ethyl]-trans cyclohexanecarboxamide; anticoagulant, antiinflammatory agent; | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009455-A1 | especially blood coagulation factor XIa and plasma kallikrein; e.g. 4-aminomethyl-[2-phenyl-1-(4-phenyl-pyridin-2-yl)-ethyl]-trans cyclohexanecarboxamide; anticoagulant, antiinflammatory agent; | F12, F11, F2 | CTSS 411/4885CTSK 227/4885CTSB 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.